RedwoodPharma

10 May 2022

Presentation:

2022 Annual General Meeting

Redwood Pharma

RedwoodPharma

2022: A year of renewal and realignment

- Redwood Pharma's mission continues to be the development of Rx and OTC (medical devices) in ophthalmology where unmet medical needs exist
- Our current focus is to bring RP501 to market in Europe
- Starting RP501 clinical trial in Europe to support a CE-mark application. Additional toxicology work underway
- Following a positive scientific advisory meeting in Jan. of 2022, we are evaluating our strategic options with RP101
- Continue to explore new ophthalmology programs that can leverage the IntelliGel drug delivery platform where we can build on synergies (i.e. controlled-release)

RedwoodPharma

The global pharmaceutical industry continues its strong growth

RedwoodPharma

Pharmaceuticals and medical device industries remain strong

- Pharmaceuticals continue strong sales over the last 2 decades
- R&D spending has grown from US$ 127bn in 2012 to US$ 200bn in 2020.



(in billion U.S. dollars)

Source: https://www.statista.com/statistics/

The market for ophthalmology products continues to grow

- The global ophthalmology drugs market was valued at USD$ 36.7bn in 2020
- Rising prevalence in eye disorders is expected to boost market growth by 6.4% CAGR through 2028
- Dry eye, AMD, glaucoma are among leading growth areas



Source: www.grandviewresearch.com

DED market overview

Global DED sales by treatment type[1] ($bn)



- Over 50 million people in the US and Europe are thought to suffer from DED, one of the most common ocular diseases
- An estimated 55% of DED sufferers consult an eye specialist, who typically recommend over-the-counter artificial tears as first-line therapy[2]
  - 50-60% of patients typically apply artificial tears twice a day, every day

1. Transparency Market Research – Dry Eye Disease Market, 2020–2030, November 2020
2. Apex Healthcare Market Research, August 2020

RedwoodPharma

DED – Effective and convenient treatments are needed[1]

There are various underlying causes of DED, and no silver bullet effective for all patients

- The first line of therapy is artificial tears, tried by 80% of all sufferers[1]
- Artificial tears alone are frequently ineffective, and in the absence of other OTC solutions, patients may turn to prescription treatments with stronger active ingredients; RP501 would address this market
- After first line therapy, treatments such as corticosteroids or cyclosporine come into play to help those with more persistent or complicated disease
- Most prescription DED products address the general patient population; more targeted therapies needed

FIRST LINE Cheap and works for the majority	SECOND LINE Short term use to combat inflammation	THIRD LINE Immunosuppression and low dose anti-inflammation	FOURTH LINE Expensive and very rare
• OTC: artificial tears, oily teardrops, eye ointment **RP501** 80% of patients	• Anti-inflammatory drugs, such as corticosteroid drops or ointments **RP101** 20m sufferers in EU & US	• Immune suppression: cyclosporine **RP101** • Long term anti-inflammation; low dose tetracycline; surgery; punctal plugs	• Serum drops, auto-transplantation of salivary glands

1. Avancia Consulting – RP101 Market research in Germany and the UK, 2018

RedwoodPharma

Bringing RP501 to market

- Solving primary customer needs: efficacy and convenience
- RP501 represents a next-generation therapy beyond ordinary artificial tears and gels. Has performance and convenience benefits of both.
- Short-term goal: EU regulatory approval to commercialize and launch RP501
- Intermediate goal: build engine of revenue growth through sales and licensing partnerships

RedwoodPharma

Challenges for coming 12 months

- Successfully completing RP501 clinical trial
- Submitting regulatory application for RP501 CE-mark in Europe
- Adding a commercial focus with a branded product and exploring new regional partnerships
- Finding possible new development projects with primary focus in ophthalmology either in prescription pharmaceuticals or medical device.

A big thanks to Gunnar Mattsson for 6 years of leadership!

We look forward to reporting more positive developments in the coming year

CONTACT

Mr. Martin Vidaeus

CEO

+46 70 232 29 29

Martin.Vidaeus@redwoodpharma.com

REDWOOD PHARMA AB (PUBL)

Ringvägen 100e, 9th Floor

118 60 Stockholm, Sweden

www.redwoodpharma.com

Nasdaq First North Growth stock market: REDW.ST